ProCE Banner Activity

ATLANTIS: Analysis of Outcomes With Single-Agent Lurbinectedin After Lurbinectedin + Doxorubicin in Relapsed SCLC

Slideset Download
Conference Coverage
A post hoc analysis of the phase III ATLANTIS trial showed that objective responses were maintained or improved in patients with relapsed SCLC who completed 10 cycles of lurbinectedin plus doxorubicin and switched to lurbinectedin monotherapy.

Released: June 08, 2022

Expiration: June 07, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab